Carver, J.R., Shapiro, C.L., Ng, A., American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects (2007) J Clin Oncol, 25, pp. 3991-4008
McMurray, J.J., Petrie, M.C., Murdoch, D.R., Clinical epidemiology of heart failure: public and private health burden (1998) Eur Heart J, 19. , 9-16
Hunt, S.A., Abraham, W.T., Chin, M.H., Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults (2009) J Am Coll Cardiol, 2009 (53), pp. e1-e90
Felker, G.M., Thompson, R.E., Hare, J.M., Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy (2000) New Engl J Med, 342, pp. 1077-1084
Kalam, K., Otahal, P., Marwick, T.H., Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction (2015) Heart, 100 (21), pp. 1673-1680
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators (1992) N Engl J Med, 327, pp. 685-691
Yusuf, S., Sleight, P., Pogue, J., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators (2000) N Engl J Med, 342, pp. 145-153
Pfeffer, M.A., Braunwald, E., Moye, L.A., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators (1992) N Engl J Med, 327, pp. 669-677
Vantrimpont, P., Rouleau, J.L., Wun, C.C., Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE investigators (1997) J Am Coll Cardiol, 29, pp. 229-236
Kalam, K., Marwick, T.H., Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis (2013) Eur J Cancer, 49, pp. 2900-2909
Common Terminology Criteria for Adverse Events (CTCAE) http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf, version 4.0. Available at: . [accessed 28.05.09]
Bird, B.R., Swain, S.M., Cardiac toxicity in breast cancer survivors: review of potential cardiac problems (2009) Clin Cancer Res, 14, pp. 14-24
Ewer, M.S., Lenihan, D.J., Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? (2008) J Clin Oncol, 26, pp. 1201-1203
Cardinale, D., Sandri, M.T., Colombo, A., Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy (2004) Circulation, 109, pp. 2749-2754
Owan, T.E., Hodge, D.O., Herges, R.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction (2006) N Engl J Med, 355, pp. 251-259
Plana, J.C., Galderisi, M., Barac, A., Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging (2014) Eur Heart J Cardiovasc Imaging, 15, pp. 1063-1093
Lenihan, D.J., Oliva, S., Chow, E.J., Cardinale, D., Cardiac toxicity in cancer survivors (2013) Cancer, 119, pp. 2131-2142
Chen, J., Long, J.B., Hurria, A., Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer (2012) J Am Coll Cardiol, 60, pp. 2504-2512
Pinder, M.C., Duan, Z., Goodwin, J.S., Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer (2007) J Clin Oncol, 25, pp. 3808-3815
Oeffinger, K.C., Mertens, A.C., Sklar, C.A., Chronic health conditions in adult survivors of childhood cancer (2006) N Engl J Med, 355, pp. 1572-1582
Reulen, R.C., Winter, D.L., Frobisher, C., Long-term cause-specific mortality among survivors of childhood cancer (2002) JAMA, 304, pp. 172-179
Schultz-Hector, S., Trott, K.R., Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? (2007) Int J Radiat Oncol Biol Phys, 67, pp. 10-18
Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C.E., Ewer, M., Keefe, D., Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 (2005) J Clin Oncol, 23, pp. 7811-7819
Perez, E.A., Suman, V.J., Davidson, N.E., Kaufman, P.A., Martino, S., Dakhil, S.R., Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial (2004) J Clin Oncol, 22, pp. 3700-3704
Suter, T.M., Cook-Bruns, N., Barton, C., Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer (2004) Breast, 13, pp. 173-183
O'Brien, M.E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer (2004) Ann Oncol, 15, pp. 440-449
Smith, I., Procter, M., Gelber, R.D., Guillaume, S., Feyereislova, A., Dowsett, M., HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial (2007) Lancet, 369, pp. 29-36
Romond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer, C.E., Davidson, N.E., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer (2005) N Engl J Med, 353, pp. 1673-1684
Ryberg, M., Nielsen, D., Cortese, G., Nielsen, G., Skovsgaard, T., Andersen, P.K., New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients (2008) J Natl Cancer Inst, 100, pp. 1058-1067
